Merck builds out cancer drug pipeline with Kelun-Biotech deal

The pharma will pay the Chinese drugmaker $175 million for access to seven preclinical antibody-drug conjugates, deepening ties established this year. 

By Ned Pagliarulo • Dec. 22, 2022

Roche, Biogen sign royalty deal for late-stage lymphoma drug

Roche will pay royalties to Biogen on glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus.

By Jonathan Gardner • Updated Dec. 26, 2022

Explore the Trendline➔

The expanding world of RNA therapies

Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

By BioPharma Dive staff

Lilly partners with Sosei to develop drugs aimed at a key family of proteins

The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

By Christopher Newman • Dec. 16, 2022

Lilly lays out ambitious plans for 2023

Expected increases in sales and spending will be accompanied by a lengthy clinical and regulatory agenda in diabetes, obesity and Alzheimer’s disease.

By Jonathan Gardner • Dec. 14, 2022

Roche pharma division head to depart amid CEO changeover

The drugmaker’s pharmaceuticals head Bill Anderson will leave on Dec. 31. Current diagnostics chief Thomas Schinecker will fill in on an interim basis before a replacement is found and Schinecker takes over as CEO in March.

By Christopher Newman • Dec. 12, 2022

[Podcast] Thinking Big for Small and Mid-Sized Biotechs

This podcast series explores how to help small and mid-sized companies get innovative treatments to the people who need them.to help small and mid-sized companies get innovative treatments to the people who need them.

By BioPharma Dive's studioID • Updated Dec. 15, 2022

How can growth-oriented pharma organizations ensure they are ‘fit for purpose’?

The pharmaceutical industry is dynamic and rapidly evolving. To compete, companies must learn to leverage the pace of change as an accelerator for both shareholder returns and patient outcomes.

Dec. 12, 2022

Novartis gets second trial win for blockbuster hopeful

The company plans to seek broad approval of the oral medication, iptacopan, next year after it met its primary endpoint in a new pool of patients with the rare blood disease PNH.

By Kristin Jensen • Dec. 8, 2022

MEI, Kyowa stop lymphoma drug trials after FDA meeting

The decision not to run a Phase 3 trial is the latest fallout from U.S. regulators’ recent moves to closely evaluate a class of drugs called PI3 kinase inhibitors. 

By Jonathan Gardner • Dec. 6, 2022

J&J drops out of hunt for Horizon, leaving Sanofi and Amgen to bid

The two remaining suitors said they would make cash bids if they move forward with offers, for which they must declare “firm intent” by Jan. 10 under Irish takeover rules.

By Christopher Newman • Dec. 5, 2022

J&J’s Duato to replace departing Gorsky as board chair

The board reshuffling will consolidate Duato’s leadership of J&J as the company absorbs a big medtech acquisition and nears a planned spin out of its consumer health division.

By Delilah Alvarado • Dec. 2, 2022

Large pharmas probe takeover of Horizon Therapeutics

The Dublin-headquartered drugmaker confirmed it is in "highly preliminary" talks with Amgen, J&J and Sanofi, although it cautioned no offer may ever materialize.

By Ned Pagliarulo • Updated Nov. 30, 2022

Roche pulls Tecentriq in bladder cancer, completing sweep of ‘dangling’ accelerated approvals

The pharma will no longer market the immunotherapy in the U.S. for urothelial carcinoma, the indication for which the drug was first approved six years ago.

By Jonathan Gardner • Nov. 29, 2022

Is your gross-to-net strategy ready for uncertainty?

Whether economic times are good, bad or somewhere in between, life science companies benefit from a holistic, centralized approach, including technological, financial, operational and regulatory considerations for GtN management and predictability of GtN rates.

Nov. 28, 2022

Novartis, research group to advance new kind of malaria drug into late-stage test

The Swiss pharma and the Medicines for Malaria Venture plan to start a Phase 3 trial of a non-artemisinin combination treatment next year.

By Delilah Alvarado • Nov. 23, 2022

Merck to buy blood cancer biotech Imago for $1.35B

The deal is Merck’s second notable acquisition in the past year and a half, part of a strategy to diversify its pipeline beyond the top-selling Keytruda.

By Christopher Newman • Nov. 21, 2022

Merck KGaA outlines plan to rev up drug R&D

The German company aims to, on average, launch a new medicine or major treatment indication every 18 months in a bid to boost its pharma business.

By Ned Pagliarulo • Nov. 21, 2022

Teva taps Sandoz veteran to take over CEO post from Schultz

Richard Francis will take over for the retiring Kåre Schultz on Jan. 1. He’ll face major challenges at Teva, including opioid settlements, biosimilar launches and reducing the company’s debt.

By Jonathan Gardner • Nov. 21, 2022

Pfizer, BioNTech start study testing next COVID-19 vaccine

The new candidate is meant to provide broader immunity over a longer period of time and is part of the companies’ strategy to stay ahead of a shifting coronavirus threat.

By Delilah Alvarado • Nov. 17, 2022

Regeneron teams up with CytomX to develop dual-targeting cancer drugs

Regeneron will pay CytomX $30 million to try to create bispecific antibody drugs that are safer and have a wider reach than existing treatments.  

By Christopher Newman • Nov. 17, 2022

Eli Lilly’s Julie Gilmore on finding up-and-coming companies and backing small biotechs

Only a small fraction of the companies Lilly evaluates get into its incubator, according to Gilmore. Here’s how the big pharma selects them.

By Gwendolyn Wu • Nov. 15, 2022

Trial failures end latest hope for Roche’s Alzheimer’s drug

Eight years after gantenerumab failed a Phase 3 study, the drug came up short in late-stage testing again, proving unable to meaningfully slow cognitive decline in two closely watched trials. 

By Delilah Alvarado , Ben Fidler • Nov. 14, 2022

Crossing the new real world data landscape

Learn about key factors and trends in RWE and why a data luminary is crucial to your success.

Nov. 14, 2022

Under FDA pressure, GSK limits use of ovarian cancer drug

The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology. 

By Jonathan Gardner • Nov. 11, 2022

EMA backs restrictions on certain immune-regulating drugs

Once the European Commission signs off, use of several so-called JAK inhibitors sold by Eli Lilly, Pfizer and other drugmakers will be limited among smokers and patients who are at high risk of certain health complications. 

By Christopher Newman • Nov. 11, 2022